Citadel Advisors’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-73
| Closed | -$531 | – | 14674 |
|
|
2023
Q3 | $531 | Buy |
+73
| New | +$489 | ﹤0.01% | 14031 |
|
|
2023
Q2 | – | Sell |
-380
| Closed | -$1.18K | – | 14694 |
|
|
2023
Q1 | $1.18K | Sell |
380
-927
| -71% | -$3.52K | ﹤0.01% | 14346 |
|
|
2022
Q4 | $5.17K | Sell |
1,307
-15,973
| -92% | -$65.2K | ﹤0.01% | 14029 |
|
|
2022
Q3 | $65K | Sell |
17,280
-9,147
| -35% | -$116K | ﹤0.01% | 11430 |
|
|
2022
Q2 | $353K | Buy |
26,427
+9,254
| +54% | +$61.5K | ﹤0.01% | 9437 |
|
|
2022
Q1 | $85K | Sell |
17,173
-20,547
| -54% | -$102K | ﹤0.01% | 12427 |
|
|
2021
Q4 | $259K | Sell |
37,720
-8,400
| -18% | -$144K | ﹤0.01% | 11261 |
|
|
2021
Q3 | $1.42M | Buy |
46,120
+38,907
| +539% | +$1.28M | ﹤0.01% | 7225 |
|
|
2021
Q2 | $234K | Buy |
7,213
+1,213
| +20% | +$41.6K | ﹤0.01% | 11822 |
|
|
2021
Q1 | $227K | Buy |
6,000
+2,960
| +97% | +$135K | ﹤0.01% | 11462 |
|
|
2020
Q4 | $144K | Buy |
+3,040
| New | +$132K | ﹤0.01% | 9973 |
|
|
2020
Q3 | – | Sell |
-5,240
| Closed | -$231K | – | 10316 |
|
|
2020
Q2 | $231K | Sell |
5,240
-2,573
| -33% | -$121K | ﹤0.01% | 8320 |
|
|
2020
Q1 | $256K | Buy |
7,813
+6,146
| +369% | +$282K | ﹤0.01% | 7591 |
|
|
2019
Q4 | $85K | Buy |
+1,667
| New | +$69.9K | ﹤0.01% | 8605 |
|
|
2019
Q3 | – | Sell |
-1,360
| Closed | -$75K | – | 9400 |
|
|
2019
Q2 | $75K | Sell |
1,360
-13
| -0.9% | -$812 | ﹤0.01% | 8616 |
|
|
2019
Q1 | $84K | Buy |
+1,373
| New | +$88.2K | ﹤0.01% | 8612 |
|
|
2018
Q4 | – | Sell |
-2,573
| Closed | -$208K | – | 9374 |
|
|
2018
Q3 | $208K | Sell |
2,573
-4,387
| -63% | -$348K | ﹤0.01% | 8157 |
|
|
2018
Q2 | $609K | Buy |
6,960
+5,347
| +331% | +$938K | ﹤0.01% | 6052 |
|
|
2018
Q1 | $312K | Buy |
+1,613
| New | +$301K | ﹤0.01% | 6678 |
|
|
2015
Q2 | – | Sell |
-6
| Closed | -$15K | – | 8855 |
|
|
2015
Q1 | $15K | Buy |
6
+5
| +500% | +$10.3K | ﹤0.01% | 8065 |
|
|
2014
Q4 | $1K | Sell |
1
-11
| -92% | -$21.2K | ﹤0.01% | 8407 |
|
|
2014
Q3 | $24K | Hold |
12
| – | – | ﹤0.01% | 7322 |
|
|
2014
Q2 | $41K | Buy |
+12
| New | +$39.2K | ﹤0.01% | 6890 |
|
|
2014
Q1 | – | Sell |
-15
| Closed | -$49K | – | 7904 |
|
|
2013
Q4 | $49K | Buy |
15
+3
| +25% | +$11.8K | ﹤0.01% | 6053 |
|
|
2013
Q3 | $52K | Buy |
12
+3
| +33% | +$12.1K | ﹤0.01% | 5775 |
|
|
2013
Q2 | $29K | Buy |
+9
| New | +$34.2K | ﹤0.01% | 5913 |
|
Other funds holding GYRE
TRCT
Citadel Advisors's GYRE Position: Q4 2023 in Review
Citadel Advisors sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 3,198 shares — an estimated $23.1K sold.
Citadel Advisors first reported a position in GYRE in Q2 2013 and held it in 27 quarters. The position peaked at $2.71M in Q1 2020. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.
- Citadel Advisors reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
- Citadel Advisors sold 3,198 Gyre Therapeutics shares in Q4 2023, an estimated $23.1K.
- Citadel Advisors first reported a position in Gyre Therapeutics in Q2 2013 and held it in 27 quarters.
- Citadel Advisors's Gyre Therapeutics position peaked at $2.71M in Q1 2020.
- 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.
Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.